Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results on February 28, 2022, at 4:30 p.m. ET. The call aims to provide insights into the company's performance and future projections. To participate, stakeholders must pre-register for the call. Additionally, a replay of the webcast will be available for 30 days post-event. Apellis is known for developing targeted C3 therapies for various diseases driven by complement cascade activation.

Positive

• Hosting a conference call to discuss full year 2021 financial results, indicating transparency with investors.
• Focus on innovative therapies targeting debilitating diseases, showcasing commitment to research.

Negative

• None.

WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 4:30 p.m. ET.

To access the live call by phone, please pre-register for the call here. The conference ID is 8184953. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

When will Apellis Pharmaceuticals announce its fourth quarter and full year 2021 financial results?

Apellis Pharmaceuticals will announce its financial results on February 28, 2022, at 4:30 p.m. ET.

How can I access the Apellis Pharmaceuticals conference call?

To access the call, you must pre-register online. The conference ID is 8184953.

Will there be a replay of the Apellis Pharmaceuticals financial results webcast?

Yes, a replay of the webcast will be available for 30 days following the event.

What is the focus of Apellis Pharmaceuticals?

Apellis Pharmaceuticals specializes in developing targeted C3 therapies for diseases driven by excessive complement activation.